Article Information
History
- December 8, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Amit Kumar Mitra1,2,3,*,
- Ujjal Kumar Mukherjee4,
- Suman Mazumder1,2,
- Vithal Madhira5,
- Timothy Bergquist6,
- Yu Raymond Shao7,
- Feifan Liu8,
- Qianqian Song9,
- Jing Su10,
- Shaji Kumar11,
- Benjamin A. Bates12,
- Noha Sharafeldin13,
- Umit Topaloglu9 and
- the National COVID Cohort Collaborative Consortium
- 1Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
- 2Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Auburn University, Auburn, AL
- 3UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
- 4University of Illinois, Urbana-Champaign, IL
- 5Palila Software LLC, Reno, NV
- 6Sage Bionetworks, Seattle, WA
- 7Duke University Medical Center, NC
- 8University of Massachusetts Chan Medical School, MA
- 9Wake Forest School of Medicine Winston-Salem, NC, USA
- 10Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
- 11Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
- 12Department of Medicine, Rutgers-RWJMS Medical School, New Brunswick, NJ
- 13School of Medicine, University of Alabama at Birmingham, Birmingham, AL
- ↵*Corresponding/Presenting Author:
Amit Kumar Mitra, PhD, Assistant Professor (Tenure-Track), Drug Discovery and Development, Director, Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Harrison College of Pharmacy, Auburn University 3306D Walker Building, Auburn, Alabama 36849, Office: 334.844.7404, Email: akm0060{at}auburn.edu
Posted December 08, 2022.
Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
